血小板から放出される製品によってプラズミノゲン活性化剤阻害剤の誘導
1Cardiovascular Division, Washington University School of Medicine, St. Louis, Missouri 63110.
Circulation
|October 1, 1990
まとめ
血小板活性化により,血中のプラズミノゲン活性化剤阻害剤-I (PAI) を増加させる成長因子が放出されます. この発見は,血小板が,心筋梗塞で観察されるPAIレベルを高めることに寄与することを示唆しています.
科学分野:
- 心血管生物学 心血管生物学
- ヘモスタシスとトランボシス
- 分子医学は分子医学である.
背景:
- 血小板活性化とプラズミノゲン活性化阻害剤 (PAI) タイプI活性性の増加は,急性心筋梗塞と関連しています.
- 血小板活性化とPAIタイプIの活性性の関係については,さらなる調査が必要である.
研究 の 目的:
- 血小板活性化とプラズマのPAIIタイプI活性との間のインビボの関係を調査する.
- PAI I型レベルを調節するにおける血小板由来成長因子の役割を決定する.
主な方法:
- エピダーマルの成長因子,変形成長因子β,血小板溶解体をウサギに注入する.
- プラズマのPAI活性とPAI1型メッセンジャーRNA発現の測定.
- 抗変換成長因子β 中和抗体の投与.
主要な成果:
- 皮膜成長因子,変形成長因子β,血小板溶解体は,投与量に依存した方法でプラズマのPAI活性を著しく増加させた.
- 血小板溶解体は,大動脈,肝臓,心筋におけるプラズマPAI1型メッセンジャーRNAが著しく上昇した.
- 抗変異成長因子β抗体は,プラズマのPAI増加を弱め,TGF-βの役割を示した.
結論:
- 血小板関連成長因子と血小板リン酸は,体内ではプラズマのPAIタイプIを増加させる.
- 血小板活性化と関連する成長因子の放出は,心筋梗塞後のプラズマPAI濃度の上昇に寄与する.
さらに関連する動画
04:37Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
Published on: May 23, 2025
08:01The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
Published on: February 27, 2026
関連する概念動画
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Introduction to Hemostasis
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized, and...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized, and...
Formation of the Platelet Plug
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Coagulation
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
Extrinsic and Intrinsic Pathways of Hemostasis
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
Clot Retraction and Fibrinolysis
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
